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CASE REPORT / OLGU SUNUMU 
Atropine-induced non-sustained polymorphic ventricular tachycardia: A rare case 
Nadir bir olgu: Atropinin indüklediği sürekli olmayan polimorfik ventriküler taşikardi
Mesut Aydın, Abdulkadir Yıldız, Nihat Polat, Halit Acet, Yahya İslamoğlu
ÖZET
Tekrarlayan çarpıntı ve presenkop şikayetleri ile 40 ya-
şında erkek hasta kardiyoloji kliniğine başvurdu. Hastanın 
öz geçmişinde herhangi bir özellik yoktu. Atriyoventriküler 
nod hastalığı veya taşiaritmi indüklemek için elektrofiz-
yolojik çalışma yapıldı. Atropin 1.0 mg yapıldıktan sonra 
testin tekrarlanması planlandı. Bu esnada polimorfik vent-
riküler taşikardi gelişti. Overdrive pacing ile taşikardi son-
lanmadı yaklaşık 2 dakika sonra spontan olarak sonlandı. 
Anahtar kelimeler: ventriküler taşikardi, atropin, presen-
kop 
ABSTRACT
A 40 years old male with history of unexplained recur-
rent presyncope and palpitation episodes referred to car-
diology department. Patient had no past medical history. 
Subsequently,  electrophysiology  study  was  performed 
to  detect  any  underlying  atrioventricular  nodal  disease 
or  inducible  tachyarrhythmias.  During  this  period,  1.0 
mg of atropine was injected intravenously to performed 
stimulation and patient suddenly developed polymorphic 
ventricular tachycardia that could not be terminated with 
overdrive pacing. Ventricular tachycardia was terminated 
spontaneously, two minutes later. J Clin Exp Invest 2014; 
5 (3): 449-451
Key  words:  ventricular  tachycardia,  atropine,  presyn-
cope
INTRODUCTION
Cardiac functions are under the influence of auto-
nomic nervous system. There is sufficient evidence 
that proves an imbalance in this autonomic regu-
lation predisposes to electrical instability and ven-
tricular tachyarrhythmias [1]. Atropine is commonly 
used in the treatment of bradyarrhythmias and in 
electrophysiologic  studies.  After  atropine  usage 
changes of autonomic balances on heart may result 
in ventricular tachyarrhythmias. Here, we report a 
case of polymorphic ventricular tachycardia (VT) in-
duced by atropine with hemodynamic deterioration 
and subsequent recovery to normal hemodynamic 
status.
CASE REPORT
A  40  years  old  male  with  history  of  unexplained 
recurrent presyncope and palpitation episodes re-
ferred to cardiology department. Presyncope was 
preceded by palpitations, shortness of breath, and 
atypical chest pain. Patient had no past medical his-
tory. On admission, vital signs were stable with an 
unremarkable physical examination. Electrocardio-
gram showed normal sinus rhythm at 74 beats per 
minute with normal intervals (Figure 1). All cardiac 
work up for presyncope including echocardiogram, 
24-hour Holter monitoring, and tilt table test were 
in  normal  limits.  Subsequently,  electrophysiology 
study was performed to detect any underlying atrio-
ventricular (AV) nodal disease or inducible tachyar-
rhythmias. Neither atrial nor VT could be induced 
by  programmed  atrial  and  ventricular  stimulation. 
Wenckebach point of AV node was 310 ms. Dur-
ing  this  period,  1.0  mg  of  atropine  was  injected 
intravenously  to  repeated  stimulation  and  patient 
developed  polymorphic  VT  that  could  not  be  ter-
minated  with  overdrive  pacing  (Figure  2,  and  3). 
Subsequently, the patient became hypotensive, felt Aydın M. et al. Atropine-induced polymorphic ventricular tachycardia 450
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lightheadness and dizziness; however, conscious-
ness  was  not  lost.  We  administered  amiodarone 
300 mg intravenously. Ventricular tachycardia was 
terminated, two minutes later (Figure 4). Bedside 
echocardiogram yielded normal cardiac structures 
without any pericardial effusion. At the same ses-
sion, coronary angiogram was performed revealing 
normal coronary arteries. Later, cardiac magnetic 
resonance imaging ruled out any cardiomyopathy.
Figure 1. Electrocardiography with sinus rhythm
Figure 2. Electrocardiography with polymorphic ventricu-
lar tachycardia
Figure 3. Simultaneous recordings of surface leads to-
gether with high right atrium, coronary sinus and ablation 
catheter electrogram with polymorphic ventricular tachy-
cardia. A: atrial depolarization, V: ventricular depolariza-
tion
Figure 4. Electrocardiography with sinus rhythm 
DISCUSSION
Most of the cardiac sudden deaths are due to ma-
lignant ventricular arrythmias [2]. The appearance 
of  ventricular  tachyarrhythmias  including  VT  and 
ventricular fibrillation following atropine therapy dur-
ing the course of heart rate acceleration has been 
described  in  the  presence  of  significant  ischemic Aydın M. et al. Atropine-induced polymorphic ventricular tachycardia 451
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heart disease [2,3]. There is clinical evidence that 
reduced vagal activity is associated with increased 
risk for life-threatening arrythmias after myocardial 
infarction, and increased vagal tone may protective 
effect against ventricular arrythmias [5]. It has been 
reported that vagal nerve stimulation exerts an anti-
arrhythmic effect in rat model of myocardial infarc-
tion [6]. In a study, a dose of 0.8-1.2 mg intravenous 
atropine was demonstrated to induce arrhythmias in 
patients with or without heart disease [7]. 
An  enhanced  sympathetic  drive  of  the  heart 
and catecholamines play a major role in the patho-
physiology of ventricular arrhythmias, whereas an 
augmented vagal tone and strong vagal stimuli de-
press sinus node activity and AV nodal propagation 
[8]. Fei et al. showed idiopathic VT episodes was 
attributed to a decrease in parasympathetic activ-
ity rather than an enhanced sympathetic activity [1]. 
Atropine-induced VT can be explained by both the 
initial decrease in parasympathetic activity and an 
unopposed sympathetic activity.
The exact mechanism responsible for the pro-
duction  of  ventricular  irritability  after  atropine  ad-
ministration is not entirely clear. Atropine induced 
tachycardia  leading  to  an  increase  in  myocardial 
oxygen demand appears to be one possible expla-
nation especially in an ischemic myocardium. The 
fibrillation threshold is lowered and the disparity of 
refractory periods becomes greater at faster rates 
when the myocardium is ischemic. This increase in 
disparity will lead to slow, nonhomogenous spread 
of impulses, resulting in reentrant activity and even-
tually ventricular fibrillation. Moreover the efflux of 
potassium  from  the  myocardial  cells  associated 
with tachycardia may have an important role in pro-
moting ventricular irritability by bringing the resting 
potential down towards the threshold potential. In-
creased extracellular potassium may also depress 
conduction and induce reentry [3,9]. The increased 
heart rate may cause ventricular extrasystoles even 
in the absence of coronary artery disease [10].
Past dog studies in which the His bundle has 
been exposed by careful dissection suggest that va-
gal stimulation or acetylcholine may have an effect 
on specialized conduction fibers at and below the 
bundle of His. Atropine by removing the parasym-
pathetic system’s inhibitory effect on the electrical 
pathways  might  possibly  cause  unopposed  sym-
pathetic  activity  [9].  This  unopposed  sympathetic 
activity may result in ventricular tachyarrhythmias. 
Considering the above mechanisms beta blockers 
can be used in patients with sensitive sympathetic 
drive to prevent VTs.
In conclusion, spontaneously developed poly-
morphic VT probably developed due to the unop-
posed  effect  of  sympathetic  nervous  system  on 
heart which was caused by atropine injection. It is 
essential to emphasize that increased sympathetic 
drive to the heart is arrhythmogenic, whereas vagal 
activity may exert a protective effect. The apparent 
provocation of arrhythmias by atropine observed in 
the present report may be an infrequent entity and 
its judicious use should be accompanied by close 
monitoring and intravenous B-blocker use if neces-
sary. Patients may have favorable outcomes with 
beta blockers.
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